Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Mary Linton B. Peters

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0905-7583; OpenAlex author ID A5020352485, A5125909585; NIH RePORTER profile ID 14667654. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
60
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 2 papers, 1 grant · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.esmoop.2026.107774↗
  2. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  3. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  4. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. Co-author DOI 10.1200/op.23.00495↗
  5. Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcita… Last author DOI 10.3390/cancers16152734↗
  6. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Co-author DOI 10.1016/j.pan.2022.05.003↗
  7. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4116↗
  8. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.32077↗
  9. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Co-author DOI 10.1097/md.0000000000018082↗
  10. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  11. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Co-author DOI 10.1016/j.pan.2018.07.009↗
  12. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Co-author DOI 10.1016/j.clinthera.2016.03.006↗

Grants 1

  1. Cost Effectiveness of Germline Genetic Testing in Pancreatic Cancer K08CA248473↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pari V. Pandharipande · 4 shared papers, 2018–2024 · strength 0.59
  2. Bruno Bockorny · 3 shared papers, 2022–2026 · strength 0.58
  3. Andrea J. Bullock · 3 shared papers, 2022–2026 · strength 0.45
  4. Chin Hur · 3 shared papers, 2018–2022 · strength 0.35
  5. Harshabad Singh · 2 shared papers, 2025–2026 · strength 0.34
  6. Leah H. Biller · 2 shared papers, 2025–2026 · strength 0.34
  7. ANDREA C Enzinger · 2 shared papers, 2025–2026 · strength 0.34
  8. Douglas Adam Rubinson · 2 shared papers, 2025–2026 · strength 0.34
  9. Srivatsan Raghavan · 2 shared papers, 2025–2026 · strength 0.34
  10. Kimmie Ng · 2 shared papers, 2025–2026 · strength 0.34
  11. Andrew J. Aguirre · 2 shared papers, 2025–2026 · strength 0.34
  12. Matthew B.B. Yurgelun · 2 shared papers, 2025–2026 · strength 0.34
  13. Brian Matthew Wolpin · 2 shared papers, 2025–2026 · strength 0.34
  14. Brandon M. Huffman · 2 shared papers, 2025–2026 · strength 0.34
  15. Jonathan Andrew Nowak · 2 shared papers, 2025–2026 · strength 0.34
  16. Kimberly J. Perez · 2 shared papers, 2025–2026 · strength 0.34
  17. James M. Cleary · 2 shared papers, 2025–2026 · strength 0.34
  18. Seohyuk Lee · 1 shared paper, 2026 · strength 0.32
  19. T.L. Correa · 1 shared paper, 2026 · strength 0.32
  20. Rodrigo Paredes · 1 shared paper, 2024 · strength 0.28
  21. Nadine A. Jackson · 1 shared paper, 2026 · strength 0.19
  22. Alan D. D’Andrea · 1 shared paper, 2026 · strength 0.19
  23. Geoffrey Ira Shapiro · 1 shared paper, 2026 · strength 0.19
  24. Chung Yin Kong · 2 shared papers, 2018–2019 · strength 0.18
  25. Angela C. Tramontano · 2 shared papers, 2018–2019 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.